Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus
Сlinical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-СoV-2 Infection Prophylactic Treatment in Republic of Belarus
Sponsor: CRO: iPharma
This PHASE3 trial investigates Covid19 and is currently ongoing. CRO: iPharma leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Oct 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Oct 2021 — Oct 2022 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 1 earlier version
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CRO: iPharma
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- Russian Direct Investment Fund
For direct contact, visit the study record on ClinicalTrials.gov .